

- Galactosemia, 336, 433e-3t, 433e-5
 α -Galactosidase A gene mutations. *See* Fabry's disease
- Galantamine, 176, 2601
- Gallavardin effect, 51e-1, 51e-3, 1450, 1531
- Gallbladder
 bile concentration within, 2076
 fistula formation in, 2081
 gangrene of, 2081
 hypomotility of, 2077
 perforations of, 2081
 porcelain, 2082
 strawberry, 2083
- Gallbladder disease, **2076**
 abdominal pain in, 103
 cancer, 285, 553
 chest discomfort/pain in, 96t, 98
 cholecystitis. *See* Cholecystitis
 clinical features of, 2079–2080
 congenital anomalies, 2076
 diagnosis of, 2078–2079, 2079f, 2079t
 gallstones. *See* Gallstone(s)
 hyperplastic cholecystoses, 2083
 natural history of, 2080
 postmenopausal hormone therapy and, 2384t, 2385
 in pregnancy, 49
- Gallium nitrate, 314, 607t
- Gallstone(s), **2076**
 asymptomatic, 2080
 biliary sludge and, 2077–2078
 cholesterol stones, 2076–2078, 2077f, 2078t
 clinical features of, 2079–2080
 complications of, 2080
 diagnosis of, 2078–2079, 2079t
 epidemiology of, 2076
 genetic considerations in, 2076–2077
 in hemolytic anemia, 399
 jaundice in, 281–282
 natural history of, 2080
 obesity and, 415e-6
 pathogenesis of, 2076
 pigment stones, 2078, 2078t
 prevention of, during weight loss, 2396
 treatment of, 2080
- Gallstone ileus, 1985, 2081–2082
- Gallstone pancreatitis, 1893–1894, 2096
- GALNT3* gene mutations, 2460
- GALT (gut-associated lymphoid tissue), 1228, 1232
- γ -aminobutyric acid (GABA)
 action of, 444e-3t
 alcohol and, 2723–2724
 clinical aspects of, 444e-3t
 metabolism, disorders of, 434e-2t
 in sleep promotion, 185, 186f
 structure of, 444e-3t
- γ -aminobutyric acid (GABA) agonists, 263
- γ -carboxylase, 736
- γ -glutamyl transpeptidase (GGTP), 1997, 2053, 2053t
- Gamma heavy chain disease (Franklin's disease), 718
- γ -hydroxybutyric acid (GHB)
 abuse of, 168, 469e-5
 action of, 469e-5
 for narcolepsy, 190
 overdose/poisoning with, 473e-10t
- Gamma knife surgery, 1792, 2263, 2646
- γ motor neurons, 155f
- γ radiation, 103e-4, 263e-1
- Ganciclovir
 action of, 214e-4, 215e-8, 897
 adverse effects of, 215e-8, 897, 2547t
 for CMV infection, 1193
 prophylaxis, 215e-8
 in transplant recipient, 139e-4t, 922, 926, 927
 treatment, 215e-2t, 215e-8, 2657
 pharmacology of, 215e-8
 resistance to, 215e-8
 for viral encephalitis, 897
- Gan Gan virus, 1306t, 1313
- Gangliocytomas, 2264
- Gangliogliomas, 601
- Ganglionopathy, dorsal root, 618, 2685
- Gangosa, 207e-2
- Gangrene
 anaerobic bacterial, 1099
 Fournier's, 831
 gallbladder, 2081
 gas. *See* Gas gangrene (clostridial myonecrosis)
 hemolytic streptococcal. *See* Necrotizing fasciitis
- GAPD (glyceraldehyde-3-phosphate dehydrogenase) deficiency, 654t
- Gap junctions, 444e-4
- Gardner-Diamond syndrome, 368
- Gardnerella vaginalis*, 150e-6. *See also* Bacterial vaginosis
- Gardner's syndrome
 clinical features of, 538t, 539, 599t
 genetic considerations in, 599t
 polyp distribution and characteristics in, 538t
 skin manifestations of, 364, 364t
 small bowel adenomas in, 536
- Garlic, 404t
- Gas, intestinal. *See* Flatus/flatulence
- Gas cysts, intestinal, 991
- Gas exchange
 in COPD, 1702
 diffusion of oxygen and carbon dioxide, 306e-3–4
 measurement of, 306e-6
 physiology of, 306e-3–4
 ventilation-perfusion heterogeneity, 306e-4, 306e-4f
- Gas gangrene (clostridial myonecrosis), **992**
 of bowel, 991
 clinical features of, 783, 992, 993f
 diagnosis of, 993, 2429
 etiology and pathogenesis of, 780t, 783, 831, 992–993, 993f
 histologic findings in, 993, 994f
 nontraumatic (spontaneous), 992, 993f
 prevention of, 994
 prognosis of, 994
 traumatic, 992
 treatment of, 780t, 832t, 833, 991t, 993–994
- GAS infections. *See* Group A *Streptococcus* (GAS) infections
- Gas-liquid chromatography, 150e-3
- Gastrectomy
 cobalamin deficiency after, 645
 complications of, 1926–1927
 for gastric adenocarcinoma, 535
 for gastric lymphoma, 536
 for peptic ulcer disease, 1925–1926
- Gastric acid, 853, 1912–1913, 1914f, 2090
- Gastric adenocarcinoma, **534**
 clinical features of, 534–535
 deaths from, 469f, 534
 diagnosis of, 535
 diffuse type, 534
 epidemiology of, 534
 etiology of, 534, 534t
 genetic considerations in, 101e-2t, 101e-6t, 1039
 global considerations in, 534
H. pylori infection and, 1039–1040, 1039f, 1922
 incidence of, 468, 534
 indigestion in, 262
 intestinal type, 534
 iron-deficiency anemia and, 535
 metastatic, 535
 pathology of, 534
 postgastrectomy, 1927
 spread by direct extension, 534
 staging of, 535t, 1885f
 treatment of, 535
 ulcers and, 534
- Gastric antral vascular ectasia, 2161, 2164
- Gastric bypass surgery. *See* Bariatric surgery
- Gastric emptying, delayed. *See* Gastroparesis
- Gastric fundic varices, 1891, 1891f
- Gastric glands, 1911, 1911f
- Gastric inhibitory peptide, ectopic production of, 609t, 611
- Gastric lavage, 319, 473e-6
- Gastric lymphoma, 535–536. *See also* Mucosa-associated lymphoid tissue (MALT) lymphoma
- Gastric neuroendocrine tumors (carcinoids), 560t, 564. *See also* Gastrointestinal neuroendocrine tumors (GI-NETs)
- Gastric outlet obstruction, 1892, 1893f, 1894f, 1918
- Gastric ulcers. *See* Peptic ulcer disease
- Gastric varices, 277
- Gastrin, 1928, 1928t
- Gastrinoma. *See also* Zollinger-Ellison syndrome (ZES)
 clinical features of, 269, 568
 in MEN 1, 1927–1928, 2336–2337, 2336t
 screening tests for, 1928, 1928t, 2337t
 treatment of, 272, 1929, 2337
- Gastritis, **1930**
 abdominal pain in, 106t
 acute, 1930, 1930t
 after cholecystectomy, 2083
 autoimmune, 372e-24t
 bleeding in, 277
 chronic, 1930–1931, 1930t
 classification of, 1930, 1930t
 eosinophilic, 1931–1932
 granulomatous, 1932
 halitosis in, 242
 lymphocytic, 1931
 multifocal atrophic, 1931
 stress-related, 277, 1929–1930
 treatment of, 1931
 type A, 1931
 type B, 1931, 1931f
 varioliform, 1931
- Gastroenteritis. *See also* Diarrhea, infectious vs. appendicitis, 1987
 eosinophilic. *See* Eosinophilic gastroenteritis
 food-related. *See* Food-related illness
Salmonella. *See* *Salmonella* spp. infections, gastroenteritis
 viral, **1285**
 adenovirus, 1286f, 1286t, 1289
 astrovirus, 1286f, 1286t, 1289
 vs. bacterial, 1287t
 calicivirus, 1286f, 1286t. *See also* Norovirus (Norwalk virus) infections
 clinical features of, 1287t
 diagnosis of, 1286t
 picobirnavirus, 1286f, 1289
 rotavirus. *See* Rotavirus infections
 sapovirus, 1285, 1286t
 torovirus, 1286f, 1289
 treatment of, 1287t
- Gastroesophageal junction, 1902, 1902f
- Gastroesophageal reflux disease (GERD), **1906**
 approach to the patient, 261–262
 asthma and, 1671
 clinical features of
 alarm symptoms, 262, 262t, 1894
 chest pain, 96t, 98, 99
 cough, 244
 dysphagia, 256
 esophagitis, 1894, 1907f
 extraesophageal, 1907
 indigestion/heartburn, 262, 1900, 1907
 nausea and vomiting, 259
 oral, 236
 complications of, 1907–1908, 1907f. *See also* Barrett's esophagus/metaplasia
 diagnosis of, 1894, 1896f, 1901–1902
 differential diagnosis of, 261, 1907
 eosinophilic esophagitis and, 1908
 epidemiology of, 261, 1906
H. pylori and, 1040
 mechanisms of, 261
 pathophysiology of, 1906–1907
 in systemic sclerosis, 2161, 2164
 treatment of, 263, 1908